Laura Devor, NP
Nurse Practitioner · Santa Fe, NMNPI 1821241399
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Astrazeneca UK Limited at 41.5% of the total. Reporting peaked in 2024 at $4,511 and has fallen 77.3% since, to $1,025 in 2025. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $65.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$3K
- Daiichi Sankyo Inc.$643
- AstraZeneca$615
- Pfizer$354
- Johnson & Johnson$315
- Novartis$191
- plus $1K from 19 others
What the payments were for
- Consulting fees$75012%
- Travel & lodging$1,94431%
- Food & beverage$3,35554%
- Education$1292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 12 | $2,563 |
| Daiichi Sankyo Inc. | 4 | $643 |
| AstraZeneca | 10 | $615 |
| Pfizer | 8 | $354 |
| Johnson & Johnson | 6 | $315 |
| Novartis | 4 | $191 |
| Mirati Therapeutics, Inc. | 3 | $145 |
| AbbVie | 7 | $140 |
| GSK | 3 | $131 |
| Novocure Inc. | 1 | $131 |
| Boston Scientific | 5 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Adaptive Biotechnologies Corporation | 1 | $119 |
| Array Biopharma Inc | 7 | $110 |
| Bristol Myers Squibb | 4 | $90 |
| Servier Pharmaceuticals LLC | 3 | $66 |
| Genmab U.S., Inc. | 3 | $64 |
| Gilead | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Genentech USA, Inc. | 2 | $39 |
| Seagen Inc. | 2 | $32 |
| Exelixis Inc. | 1 | $24 |
| Incyte Corporation | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,178 in reported general payments places this provider in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 22 | $318,758 |
| Abiraterone Acetate | 23 | $90,663 |
| EliquisApixaban | 16 | $11,280 |
| Ondansetron OdtOndansetron | 25 | $296 |
| Acyclovir | 19 | $278 |
| Dexamethasone | 21 | $259 |
| Hydroxyurea | 14 | $214 |
| Prednisone | 32 | $141 |
| Levothyroxine Sodium | 20 | $132 |
| Potassium Chloride | 15 | $119 |
| Oxycodone Hcl | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $90 | $318,75822 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $121 | $90,66323 claims |
| PfizerEliquis | $354 | $11,28016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Other nurse practitioner in Santa Fe
- Ryan CommiskeySanta Fe$18K
- Jennifer PenningSanta Fe$5K
- Jennifer PorterSanta Fe$3K
- Lissa ShafferSanta Fe$2K
- Eliezer PanganSanta Fe$2K
- Marisa EscobarAlbuquerque$36K
- Catherine SollerAlbuquerque$33K
- Lauren HeckethornRio Rancho$14K
- Christina ParksAlbuquerque$7K
- Paula JohnsonAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.